Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

BIIB
Biogen Inc
stock NASDAQ

At Close
3/27/2023 3:59:53 PM EDT
269.91USD-0.044%(-0.12)606,288
215.85Bid   269.99Ask   54.14Spread IEX
Pre-market
3/27/2023 9:29:30 AM EDT
270.09USD+0.022%(+0.06)0
After-hours
3/27/2023 4:00:30 PM EDT
269.98USD+0.026%(+0.07)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
38.998B
CEO
Michel Vounatsos
Headquarters
Cambridge, Massachusetts, USA
Industry
Drug Manufacturers-General
Next Earnings
2023-05-03 (36d)
Last Split
2001-01-183for1
Related
AMGNCELGGILDSGMOACORBIOJNJPFESNYABBVXLV
BIIB Stats
Avg. Vol. 10 Day
884,925
Avg. Vol. 30 Day
900,654
Employees
8,725
Market Cap
38,998,120,712
Shares Out.
144,485,646
Float
144,056,524
P/E Ratio
12.80
EPS (ttm)
20.870
On/Off Exchange
66%/34%
6 Month Beta
0.73
1 Year Beta
0.94
2 Year Beta
0.82
3 Year Beta
0.50
52 Week Low
187.16
52 Week High
311.88
SMA50
271.75
SMA200
271.90
1 Week
+1.41%
1 Month
+0.02%
3 Month
-1.51%
6 Month
-2.42%
1 Year
+27.51%
2 Year
-2.24%
5 Year
-0.70%
Jan 31, 2022
07:34AM EST  Biogen Announces Nancy Leaming And Brian Posner To Retire From Board   RTTNews
07:30AM EST  Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogens Board of Directors, effective at the time of the Companys 2022 annual meeting of stockholders.   GlobeNewswire Inc
Jan 28, 2022
10:01AM EST  Hearing Dealreporter Reports Aurinia Pharma Said To Be On Biogen's Takeover Radar   Benzinga
08:21AM EST  The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron   Benzinga
Jan 27, 2022
09:44PM EST  Samsung Biologics agreed to buy Biogen Inc.'s (BIIB) equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion, the companies said in a statement.   RTTNews
More News
Profile
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

BIIB Stock Summary

Biogen Inc (NASDAQ:BIIB) stock price today is $269.91, and today's volume is 606,288. BIIB is down -0.044% today. The 30 day average volume is 900,654. BIIB market cap is 38.998B with 144,485,646 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC